Compare RBKB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | NYXH |
|---|---|---|
| Founded | 1860 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.9M | 165.0M |
| IPO Year | 2018 | 2021 |
| Metric | RBKB | NYXH |
|---|---|---|
| Price | $13.11 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 100.4K | ★ 240.8K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 215.00 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $2,984,000.00 | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $29.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.41 | $1.26 |
| 52 Week High | $17.99 | $6.87 |
| Indicator | RBKB | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 47.90 |
| Support Level | $11.63 | $1.28 |
| Resistance Level | $16.55 | $1.70 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 80.82 | 19.12 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.